{
    "clinical_study": {
        "@rank": "48492", 
        "arm_group": [
            {
                "arm_group_label": "CL-108", 
                "arm_group_type": "Experimental", 
                "description": "CL-108 hydrocodone 7.5 mg,APAP 325 mg, Promethazine 12.5 mg"
            }, 
            {
                "arm_group_label": "Norco", 
                "arm_group_type": "Active Comparator", 
                "description": "Commercial product containing hydrocodone 7.5 mg. APAP 325 mg"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "CL-108 formulation without API"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a double-blind, randomized, multiple-dose, placebo- and positive-controlled study of\n      CL-108 (hydrocodone 7.5 mg/APAP 325 mg, promethazine 12.5 mg) in patients with moderate to\n      severs pain following surgical removal of impacted third molar teeth.\n\n      A positive control ( Norco, A commercial formulation of hydrocodone 7.5 mg/APAP 325 mg) is\n      included to determine the anti-emetic effects of CL-108."
        }, 
        "brief_title": "Phase III Study of the Safety and Efficacy of Cl-108 in the Treatment of Moderate to Severe Pain", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Pain", 
            "Nausea", 
            "Vomiting"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Nausea", 
                "Vomiting"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Determination of being likely or possibly nausea-prone.\n\n          -  Male or non-pregnant and non-lactating female.\n\n          -  Surgical extraction of at least 2 impacted third molar teeth\n\n          -  A female of child-bearing potential is eligible to participate in this study if  she\n             has a negative urine pregnancy test and is using an acceptable method of birth\n             control.\n\n          -  Surgical extraction of  at least 2 impacted third molar teeth.\n\n          -  Presence of at least moderate post-operative pain.\n\n        Exclusion Criteria:\n\n          -  Medial Condition, presence of a serious medical condition.\n\n          -  Active local infection.\n\n          -  Drug Allergy history of hypersensitivity to an Opioid, Promethazine, Acetaminophen.\n\n          -  Caffeine use since midnight before the operation.\n\n          -  Use of an IND Drug within past 30 days.\n\n          -  Previous participation in this study.\n\n          -  Pregnant or lactating.\n\n          -  Employee of the PI,sub-investigator or Charleston Labs or relative of an employee."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "810", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01780428", 
            "org_study_id": "CLCT-002"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "CL-108", 
                    "Norco"
                ], 
                "intervention_name": "CL-108", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Norco", 
                    "Placebo"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Pain", 
            "Nausea", 
            "Vomiting"
        ], 
        "lastchanged_date": "January 30, 2013", 
        "link": {
            "description": "Charleston Website", 
            "url": "http://www.charlestonlabs.com"
        }, 
        "location": {
            "contact": {
                "last_name": "Stacey A Secreto, Med. Tech.", 
                "phone": "215-746-8871"
            }, 
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19104-6030"
                }, 
                "name": "University of Pennsylvania"
            }, 
            "investigator": {
                "last_name": "Elliot V HErsh, D.M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Double-Blind, Randomized, Placebo-Controlled, Multiple-dose Multi-Center Phase III Study of the Safety and Efficacy of Cl-108 in the Treatment of Moderate to Severe Pain", 
        "other_outcome": [
            {
                "description": "After data lock.", 
                "measure": "Elimination of vomiting in patients treated with an opioid-containing pain reliever.", 
                "safety_issue": "No", 
                "time_frame": "6 hours and 24 hours"
            }, 
            {
                "description": "After data lock.", 
                "measure": "Elimination of nausea in patients treated with an opioid-containing pain reliever.", 
                "safety_issue": "No", 
                "time_frame": "6 hours and 24 hours"
            }
        ], 
        "overall_contact": {
            "email": "bschachlet@charlestonlabs.com", 
            "last_name": "Benard P Schachtel, M.D.", 
            "phone": "5615757330"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "After data has been locked.", 
                "measure": "To compare the occurrence and severity of opioid-induced nausea and vomiting (OINV) associated with CL-108 to Norco.", 
                "safety_issue": "No", 
                "time_frame": "Over the first 24 hours"
            }, 
            {
                "description": "After data has been locked.", 
                "measure": "To demonstrate the efficacy of CL-108 when compared to placebo for the relief of pain following surgical removal of impacted third molar teeth.", 
                "safety_issue": "No", 
                "time_frame": "over 24 hours (SPID24)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01780428"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Charleston Laboratories, Inc", 
            "investigator_full_name": "John Ameling", 
            "investigator_title": "Vice-President", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "After data lock.", 
                "measure": "Reduction of the severity of nausea in patients treated with an opioid-containing pain reliever.", 
                "safety_issue": "No", 
                "time_frame": "over 6 hours"
            }, 
            {
                "description": "After data lock.", 
                "measure": "Reduction of vomiting in patients treated with an opioid-containing pain reliever.", 
                "safety_issue": "No", 
                "time_frame": "over 6 hours"
            }
        ], 
        "source": "Charleston Laboratories, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Charleston Laboratories, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}